These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19439507)

  • 21. The effects of gonadectomy on bone size, mass, and volumetric density in growing rats are gender-, site-, and growth hormone-specific.
    Zhang XZ; Kalu DN; Erbas B; Hopper JL; Seeman E
    J Bone Miner Res; 1999 May; 14(5):802-9. PubMed ID: 10320529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of growth hormone on accretion of bone mass.
    Monson JP; Drake WM; Carroll PV; Weaver JU; Rodriguez-Arnao J; Savage MO
    Horm Res; 2002; 58 Suppl 1():52-6. PubMed ID: 12373015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement.
    Holmes SJ; Whitehouse RW; Economou G; O'Halloran DJ; Adams JE; Shalet SM
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):3-7. PubMed ID: 7889628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency.
    Janssen YJ; Doornbos J; Roelfsema F
    J Clin Endocrinol Metab; 1999 Jan; 84(1):279-84. PubMed ID: 9920096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone therapy and fracture risk in the growth hormone-deficient adult.
    Johannsson G; Ohlsson C
    Baillieres Clin Endocrinol Metab; 1998 Jul; 12(2):233-50. PubMed ID: 10083894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
    Gonc EN; Kandemir N
    Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures].
    Kuzma M; Payer J
    Cas Lek Cesk; 2010; 149(5):211-6. PubMed ID: 20629339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease.
    Johannsson G; Sunnerhagen KS; Svensson J
    Clin Endocrinol (Oxf); 2004 May; 60(5):550-9. PubMed ID: 15104557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of growth hormone replacement therapy on bone markers and bone mineral density in growth hormone-deficient adults.
    Nilsson AG
    Horm Res; 2000; 54 Suppl 1():52-7. PubMed ID: 11146380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years.
    Bechtold S; Ripperger P; Bonfig W; Schmidt H; Bitterling H; Häfner R; Schwarz HP
    J Rheumatol; 2004 Jul; 31(7):1407-12. PubMed ID: 15229964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
    Underwood LE; Attie KM; Baptista J;
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5273-80. PubMed ID: 14602761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in bone mineral density after discontinuation and early reinstitution of growth hormone (GH) in patients with childhood-onset GH deficiency.
    Benbassat CA; Wasserman M; Laron Z
    Growth Horm IGF Res; 1999 Oct; 9(5):290-5. PubMed ID: 10543936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
    Biller BM; Sesmilo G; Baum HB; Hayden D; Schoenfeld D; Klibanski A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis.
    Gillberg P; Mallmin H; Petrén-Mallmin M; Ljunghall S; Nilsson AG
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4900-6. PubMed ID: 12414848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone markers and bone mineral density during growth hormone treatment in children with growth hormone deficiency.
    Cowell CT; Woodhead HJ; Brody J
    Horm Res; 2000; 54 Suppl 1():44-51. PubMed ID: 11146379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
    Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of GH treatment on bone mass in children with GH deficiency.
    Baroncelli GI; Saggese G
    J Endocrinol Invest; 2005; 28(10 Suppl):23-7. PubMed ID: 16550718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass.
    Valk NK; Erdtsieck RJ; Algra D; Lamberts SW; Pols HA
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):317-24. PubMed ID: 7586601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.